Valsartan inhibits Angiotensin II-induced proliferation of vascular smooth muscle cells via regulating the expression of mitofusin 2

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 32, Issue 1, 2012, Pages 31-35

  Liao, Hua ^a,b   Gong, Junrong ^a   Zhang, Wenjuan ^a   Guo, Xiaomei ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CENTRAL HOSPITAL OF WUHAN   (China)

Author keywords

Angiotensin II; Proliferation; mitofusin 2; Valsartan; Vascular smooth muscle cells

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; DRUG DERIVATIVE; MEMBRANE PROTEIN; MITOCHONDRIAL PROTEIN; MITOFUSIN 2 PROTEIN, RAT; TETRAZOLE DERIVATIVE; VALINE; VALSARTAN;

ANIMAL; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECT; DRUG INTERACTION; GENE EXPRESSION REGULATION; MALE; METABOLISM; PHYSIOLOGY; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WISTAR KYOTO RAT;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; DRUG INTERACTIONS; GENE EXPRESSION REGULATION; MALE; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MITOCHONDRIAL PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RATS; RATS, INBRED WKY; TETRAZOLES; VALINE;

EID: 84861129072     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-012-0005-y     Document Type: Article

References (26)

1. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation, 1998, 98(1):82-89
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation, 2011, 123(4): e18-e209
3. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J, 1999, 138(5 Pt 2):S419-S420
4. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med, 2002, 8(11):1249-1256
5. Andrés V, Castro C. Antiproliferative strategies for the treatment of vascular proliferative disease. Curr Vasc Pharmacol, 2003, 1(1):85-98
6. Charron T, Nili N, Strauss BH. The cell cycle: a critical therapeutic target to prevent vascular proliferative disease. Can J Cardiol, 2006, 22(Suppl B):41B-55B
7. Brasier AR, Recinos A 3rd, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol, 2002, 22(8):1257-1266
8. Vaughan DE. Angiotensin and vascular fibrinolytic balance. Am J Hypertens, 2002, 15(1 Pt 2):3S-8S
9. Chen KH, Guo X, Ma D, et al. Dysregulation of HSG triggers vascular proliferative disorders. Nat Cell Biol, 2004, 6(9):872-883
10. Eguchi S, Matsumoto T, Motley ED, et al. Identification of an essential signaling cascade for mitogen-activated protein kinase activation by angiotensin II in cultured rat vascular smooth muscle cells. Possible requirement of Gq-mediated p21ras activation coupled to a Ca2+/ calmodulin-sensitive tyrosine kinase. J Biol Chem, 1996, 271(24):14 169-14 175
11. Chen KH, Wang F, Zhang J, et al. Cloning and expression of a novel partial cDNA related to hypertension. Chin Med J (Engl), 1998, 111(4):383-384
12. Bach D, Pich S, Soriano FX, et al. Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J Biol Chem, 2003, 278(19):17 190-17 197
13. Guo XM, Chen KH, Guo YH, et al. Mitofusin 2 triggers vascular smooth muscle cell apoptosis via mitochondrial death pathway .Circ Res, 2007, 101(11):1113-1122
14. Black HR, Bailey J, Zappe D, et al. Valsartan: more than a decade of experience. Drugs, 2009, 69(17):2393-2414
15. Mueck AO, Seeger H, Lippert TH. Valsartan inhibits angiotensin II -stimulated proliferation of smooth muscle cells from human coronary artery. Int J Clin Pharmacol Ther, 1999, 37(7):365-366
16. Kohno M, Ohmori K, Nozaki S, et al. Effects of valsartan on angiotensin II -induced migration of human coronary artery smooth muscle cells. Hypertens Res, 2000, 23(6):677-681
17. Chien KR, Hoshijima M. Unravelling Ras signals in cardiovascular disease. Nat Cell Biol, 2004, 6(9):807-808.
18. Wu L, Li Z, Zhang Y, et al. Adenovirus-expressed human hyperplasia suppressor gene induces apoptosis in cancer cells. Mol Cancer Ther, 2008, 7(1):222-232
19. Zhou W, Chen KH, Cao W, et al. Mutation of the protein kinase A phosphorylation site influences the anti-prolifera tive activity of mitofusin 2. Atherosclerosis, 2010, 211(1): 216-223
20. Bokemeyer D, Lindemann M, Kramer HJ. Regulation of mitogen-activated protein kinase phosphatase-1 in vascular smooth muscle cells. Hypertension, 1998, 32(4):661-667
21. Keenan SM, Bellone C, Baldassare JJ. Cyclin-dependent kinase 2 nucleocytoplasmic translocation is regulated by extracellular regulated kinase. J Biol Chem, 2001, 276(25):22 404-22 409
22. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev, 2000, 52(4):639-672
23. Ohtsu H, Suzuki H, Nakashima H, et al. Angiotensin II signal transduction through small GTP-binding proteins: mechanism and significance in vascular smooth muscle cells. Hypertension, 2006, 48(4):534-540
24. Eguchi S, Numaguchi K, Iwasaki H, et al. Calcium- dependent epidermal growth factor receptor transactivation mediates the angiotensin II -induced mitogen- activated protein kinase activation in vascular smooth muscle cells. J Biol Chem, 1998, 273(15):8890-8896
25. Feng TC, Ying WY, Hua RJ, et al. Effect of valsartan and captopril in rabbit carotid injury. Possible involvement of bradykinin in the antiproliferative action of the renin-angiotensin blockade. J Renin Angiotensin Aldosterone Syst, 2001, 2(1):19-24
26. Yamamoto T, Sata M, Fukuda D, et al. The angiotensin II type 1 receptor blocker valsartan attenuates graft vasculopathy. Basic Res Cardiol, 2005, 100(1):84-91